Successfully managing company’s first foray into gene-therapy
A biotech was planning to launch its first gene therapy, a hemophilia treatment. They wanted to gain a greater understanding of the key stakeholders, health care systems, and pre-empt likely challenges in the gene therapy market to best prepare for a successful launch.
Tracking competitive activity to improve launch readiness
A biotech company developing an asset for two rare disease indications was seeking to understand the changing competitive landscape and how this could impact its launch plans. The company also wanted to pressure-test several launch scenarios.
Optimizing clinical trial design for successful access
A large biotech was developing a new PD-1 immuno-oncology asset in Phase III clinical trials across eight solid tumors made more challenging by an intensely crowded oncology space. As part of its commercialization plan, the client wanted understand how to optimize clinical trial designs in order to achieve successful market access in US, EU5, China and Japan. ADD PRO instrument wanted to understand how best of optimize them
The P4A team provided us with a series of comprehensive analytical reports and workshops on our key competitors that helped to bolster our strategy towards launch.
Market Access Director
Working with P4A really helped us understand the practical steps needed for a successful gene therapy launch.
Global Gene Therapy Lead
By working with P4A to develop a clear understanding of the environment and requirements for HTA authorities, we are able to confidently move our asset forward into the next phase of development
Health Economics & Outcomes Research Lead